Rational Vaccines
Investigational-stage infectious disease company developing rationally engineered, live-attenuated viral immunotherapeutic and prophylactic vaccine candidates focused on herpes simplex virus types 1 and 2 (HSV-1, HSV-2). The company advances live-attenuated vaccine design, preclinical evaluation in multiple animal models, serological assay development, and regulatory enabling work toward early-phase clinical testing. It also adapts its platform for broader applications, including SARS-CoV-2 serology and viral vector formats.
Industries
Nr. of Employees
small (1-50)
Rational Vaccines
Woburn, Massachusetts, United States
Products
RVx-201
Lead therapeutic HSV vaccine candidate designed with targeted attenuation in the ICP0 gene to treat HSV-1 and HSV-2 infections.
RVx-2001
Prophylactic HSV vaccine candidate in the HSV-2 vaccine platform pipeline.
RVx-1001
Prophylactic HSV vaccine candidate in the HSV-1 vaccine platform pipeline.
Multiplex serological IgG assay (ABVIC approach)
Serological assay approach that interrogates antibodies to multiple viral proteins and can subtract cross-reacting antibodies to improve sensitivity and specificity for HSV and SARS-CoV-2 antibody detection.
HSV viral vector adaptations
Development effort to adapt HSV immunotherapeutic candidates into viral vector formats for delivery of heterologous antigens (platform expansion).
live attenuated viral immunotherapeutic and prophylactic vaccine candidates
Rational Vaccines develops rationally engineered, live attenuated viral immunotherapeutic and prophylactic vaccine candidates focused on combating diseases from herpes simplex virus 1 (HSV-1) and herpes simplex virus 2 (HSV-2) infections.
RVx-201
Lead therapeutic HSV vaccine candidate designed with targeted attenuation in the ICP0 gene to treat HSV-1 and HSV-2 infections.
RVx-2001
Prophylactic HSV vaccine candidate in the HSV-2 vaccine platform pipeline.
RVx-1001
Prophylactic HSV vaccine candidate in the HSV-1 vaccine platform pipeline.
Multiplex serological IgG assay (ABVIC approach)
Serological assay approach that interrogates antibodies to multiple viral proteins and can subtract cross-reacting antibodies to improve sensitivity and specificity for HSV and SARS-CoV-2 antibody detection.
HSV viral vector adaptations
Development effort to adapt HSV immunotherapeutic candidates into viral vector formats for delivery of heterologous antigens (platform expansion).
live attenuated viral immunotherapeutic and prophylactic vaccine candidates
Rational Vaccines develops rationally engineered, live attenuated viral immunotherapeutic and prophylactic vaccine candidates focused on combating diseases from herpes simplex virus 1 (HSV-1) and herpes simplex virus 2 (HSV-2) infections.
Expertise Areas
- Live-attenuated vaccine development
- HSV vaccine research and development
- Preclinical animal model testing (mice, guinea pigs, NHPs)
- Serological assay development and validation
Key Technologies
- Live-attenuated viral vaccine platforms
- HSV-based viral vector platforms
- Rational genetic attenuation (targeted gene mutation)
- Multiplex serological IgG assays with cross-reactivity subtraction
News & Updates
Presentation reviewing five-year safety follow-up of Phase 1 first-in-human study of the lead vaccine candidate RVx201.
Company participation at BIO International Convention.
Preclinical study demonstrating that a live-attenuated HSV-1 vaccine candidate provided robust protection against ocular HSV-1 infection in a mouse model, with protection correlated to CD8+ T cells.
Press release announcing a clinical trial to determine baseline characteristics of patients diagnosed with recurrent symptomatic HSV-2.
Multiple referenced peer-reviewed publications reporting preclinical efficacy, immunogenicity, and safety data for live-attenuated HSV vaccine candidates and related immunology.
Presentation reviewing five-year safety follow-up of Phase 1 first-in-human study of the lead vaccine candidate RVx201.
Company participation at BIO International Convention.
Preclinical study demonstrating that a live-attenuated HSV-1 vaccine candidate provided robust protection against ocular HSV-1 infection in a mouse model, with protection correlated to CD8+ T cells.
Press release announcing a clinical trial to determine baseline characteristics of patients diagnosed with recurrent symptomatic HSV-2.
Multiple referenced peer-reviewed publications reporting preclinical efficacy, immunogenicity, and safety data for live-attenuated HSV vaccine candidates and related immunology.